Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LUNG Clear all
Completed No phase listed Observational

Impact of Caregiver Depression on Asthma in the Child

NCT00223288
View directory record Official record
Conditions
Depressive Disorder, Major, Asthma
Interventions
Lexapro
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Sep 17, 2026, 9:35 PM EDT
Completed No phase listed Observational

Investigating Immune Escape by SARS-CoV-2 Variants

NCT05171803
View directory record Official record
Conditions
COVID-19; Immunity
Interventions
No intervention
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Dimas, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 17, 2026, 9:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2
Combination Product
Lead sponsor
Spirovant Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Kansas City, Kansas • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 17, 2026, 9:35 PM EDT
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Not applicable Interventional Results available

International EXPAND Lung Pivotal Trial

NCT01963780
View directory record Official record
Conditions
Lung Transplant
Interventions
OCS Lung Preservation
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Not applicable Interventional

Preparing Family Caregivers to Make Medical Decisions for Their Loved Ones

NCT02429479
View directory record Official record
Conditions
Neoplasms, Heart Failure, Kidney Diseases, Lung Diseases
Interventions
Making Your Wishes Known, Standard advance care planning
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 17, 2026, 9:35 PM EDT
Terminated Phase 1 Interventional

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

NCT06364696
View directory record Official record
Conditions
Solid Tumor
Interventions
ASP4396
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
INC280 single agent, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 17, 2026, 9:35 PM EDT
Terminated Phase 2 Interventional Results available

Genetic Predictors of Benefit to Pembrolizumab

NCT02710396
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Not applicable Interventional Results available

Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma

NCT01382446
View directory record Official record
Conditions
Ventilator Associated Pneumonia
Interventions
Chlorhexidine gluconate, Toothpaste
Drug · Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 17, 2026, 9:35 PM EDT
Recruiting Phase 2 Interventional

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

NCT05669846
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Not listed Phase 3 Interventional

Effect of Reslizumab in Chronic Rhinosinusitis

NCT02799446
View directory record Official record
Conditions
Sinusitis
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Joshua S. Jacobs
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions

NCT03097627
View directory record Official record
Conditions
Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
Interventions
ICG Intervention, Near Infrared Camera
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC

NCT02658097
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Pembrolizumab, Single Fraction Radiation Therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 17, 2026, 9:35 PM EDT
Active, not recruiting Phase 1 Interventional

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

NCT05902520
View directory record Official record
Conditions
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Interventions
DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
Biological
Lead sponsor
AgonOx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting Lung Infections Through Vibration

NCT02056860
View directory record Official record
Conditions
Lung Infection
Interventions
Group 1 will receive 15 Hz, Group 2 will receive 30 Hz, Group 3 will receive 60 Hz, Group 4 will receive 100 Hz, Phase II Optimal Frequency
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 17, 2026, 9:35 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Terminated Phase 1 Interventional

A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

NCT02111824
View directory record Official record
Conditions
Lung Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases
Interventions
MIMIG System, Indocyanine Green (ICG)
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 17, 2026, 9:35 PM EDT
Withdrawn Phase 2 Interventional

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

NCT03419559
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
LN-145, Durvalumab
Biological · Drug
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 17, 2026, 9:35 PM EDT
Recruiting Phase 1 Interventional

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT06603246
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
Interventions
GDC-6988
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Completed Phase 1 Interventional Results available

Intratumoral Cisplatin for Resectable NSCLC

NCT04809103
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
cis-diamminedichloroplatinum
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 17, 2026, 9:35 PM EDT
Withdrawn No phase listed Observational

Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing

NCT01275703
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 17, 2026, 9:35 PM EDT